Oxbryta FDA Approval History
FDA Approved: Yes (First approved November 25, 2019)
Brand name: Oxbryta
Generic name: voxelotor
Dosage form: Tablets
Company: Global Blood Therapeutics, Inc.
Treatment for: Anemia, Sickle Cell
Oxbryta (voxelotor) is an oral, HbS (sickle hemoglobin) polymerization inhibitor for the treatment of patients with sickle cell disease (SCD).
Development Timeline for Oxbryta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.